Rubius Therapeutics Inc expected to post a loss of 58  cents a share - Earnings Preview

Rubius Therapeutics

06/05/2022 19:37

* Rubius Therapeutics Inc  RUBY.OQ   RUBY.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10. 
    * ​Refinitiv's mean analyst estimate for Rubius Therapeutics
Inc
is for a loss of 58 cents per share. For the same quarter last
year, the company reported a loss of 51 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $5​, above​ its last closing price of $1.47.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.60       -0.59      -0.61     Missed  -3
 Sep. 30 2021  -0.57       -0.57      -0.55     Beat    3.2
 Jun. 30 2021  -0.50       -0.49      -0.56     Missed  -14.7​
 Mar. 31 2021  -0.53       -0.52      -0.51     Beat    1.3
 ​​Dec.        -0.52       -0.49      -0.50     Missed  -1
 31 2020                                                
 Sep. 30 2020  -0.49       -0.49      -0.51     Missed  -3.4​
 Jun. 30 2020  -0.50       -0.50      -0.47     Beat    6.5
 Mar. 31 2020  -0.55       -0.56      -0.60     Missed  -8
 This summary was machine generated May 6 at 18:36 GMT.  All
figures in US dollars  unless otherwise stated